FLT3 and acute myeloid leukemia: The addition of midostaurin to induction and consolidation therapy in patients with newly diagnosed AML at a dose of 50 mg twice daily resulted in an 80% CR rate; the OS rate at 1 and 2 years was similar irrespective of FLT3 mutation status [44].